Skip to main content
Clinical Trials/NCT02855541
NCT02855541CompletedNot Applicable

Health Effects of Increasing Muscle Activation While Sitting in Office Workers

University of Colorado, Boulder2 sites in 1 country25 target enrollmentStarted: August 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
25
Locations
2
Primary Endpoint
Maximum Oxygen Consumption

Study Overview

Brief Summary

Previous research suggests that prolonged sitting increases risk for cardiometabolic diseases and the risk factors associated with cardiometabolic diseases. However, no study to date has examined if a chronic intervention that breaks up prolonged sitting in a real-world environment results in a reduction in the metabolic risk factors associated with cardiometabolic diseases. Thus, the objective of this study is to examine the potential health benefits of breaking up sitting bouts throughout the workday using a small cycling device (DeskCycle) in office workers involved with jobs that require prolonged bouts of sitting. The investigators hypothesize that breaking up sitting will be associated with improvements in cardiometabolic disease risk factors. More specifically, the investigators hypothesize that breaking up sitting will decrease blood glucose during an oral glucose tolerance test (OGTT), increase cardiorespiratory fitness (VO2max), decrease blood pressure, decrease body fat, increase HDL cholesterol, and decrease LDL cholesterol, total cholesterol, and triglycerides.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
18 Years to 55 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Both males and females
  • Subjects will need to be 18-55 years old
  • Subjects will need to be sitting at least 6 hours/day on 5 days/week
  • Subjects will need to be exercising less than 5 hour/week

Exclusion Criteria

  • Females that are pregnant or breast-feeding.
  • Subjects must be free from any acute or chronic physical condition that would influence the outcome measures of the protocol. Examples include, but are not limited to advanced chronic disease states (chronic kidney, liver, heart, or lung disease), morbid obesity, emphysema, and an inability to use the legs for normal locomotion. Normality will be established on the basis of clinical history, physical exam, and vital signs. Any subject with a history of an uncontrolled metabolic disorder/disease or symptoms of active illness will be excluded from study. Any subject with a history of an uncontrolled metabolic disorder/disease such as diabetes (Type I or Type II) or symptoms of active illness will be excluded from study.
  • Subjects will be excluded if they have a fasted blood glucose level >126 mg/dl or a systolic blood pressure >140 mmHg.
  • Medical/psychiatric/sleep disorders history: any clinically significant unstable medical or psychological condition within the last year (treated or untreated).
  • Drug use:
  • Use of any medications, including over-the-counter and herbal products, that may affect metabolic function within 1 month prior to the study or need to use any of these medications at any time during the study (self-report by interview). Examples of potential medications that will exclude a subject include: beta-adrenergic blockers, sulfonylureas, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, and dipeptidyl peptidase IV inhibitors. Note, subjects may be tested at a later date.
  • Use of any investigational drug within 1 month before the study

Outcomes

Primary Outcomes

Maximum Oxygen Consumption

Time Frame: Measured after 4 weeks

Maximum oxygen consumption (VO2max) will be used to determine physical fitness

Blood Glucose

Time Frame: Measured after 4 weeks

2-h Post Oral Glucose Tolerance Test Blood Glucose

Secondary Outcomes

  • Systolic Blood Pressure(Measured after 4 weeks)
  • LDL Cholesterol(Measured after 4 weeks)
  • Lean Mass(Measured after 4 weeks)
  • HDL Cholesterol(Measured after 4 weeks)
  • Fat Mass(Measured after 4 weeks)
  • Triglycerides(Measured after 4 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

James Peterman

Graduate Student

University of Colorado, Boulder

Study Sites (2)

Loading locations...

Similar Trials

Health Effects of Increasing Muscle... | Clinical Trial